๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nagpur
Clinical trial register · India

Clinical Trials in Nagpur

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 332 Mumbai 259 Hyderabad 237 Bangalore 193 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca16 Eli Lilly and Company14 Bristol-Myers Squibb12 Novo Nordisk A/S9 Sanofi6
Site location
New Delhi332 Mumbai259 Hyderabad237 Bangalore193 Pune189
All 274 locations
Target enrolment
to
124 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
By invitation
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT07256392Chronic Spontaneous Urticaria
Celldex Therapeutics
Phase 3
1,370
Nagpur, Nashik, Pune
2025-11-25
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2/3
500
Ahmedabad, Gurugram, Bengaluru, Mumbai, Nagpur, New Delhi, Howrah
2025-11-05
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
Eli Lilly and Company
Phase 3
1,205
Aligarh, Jaipur, Kolkata, Kozhikode, Nagpur, Nashik, New Delhi, Rishikesh
2025-10-31
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
Eli Lilly and Company
Phase 3
1,000
Ahmedabad, Belagavi, Belgavi, Bhubaneswar, Chandigarh, Chennai, Hyderabad, Nagpur
2025-09-30
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336Ulcerative Colitis
Genentech, Inc.
Phase 2
224
Hyderabad, Rajkot, Nagpur, Jaipur, Kolkata
2025-09-29
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
Bristol-Myers Squibb
Phase 2/3
600
Mumbai, Nagpur, New Delhi, Chennai, Hyderabad, Varanasi
2025-09-11
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Belagavi, Belgavi, Jaipur, Kanpur, Kozhikode, Lucknow, Nagpur, Nashik
2025-09-02
Active, closed
Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India
NCT07109297RSV Immunization
Sanofi
Phase 4
110
Bengaluru, Jaipur, Kolkata, Nagpur, New Delhi, Pune, Vizianagaram
2025-07-31
Recruiting
EASi-PROTKTโ„ข - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Boehringer Ingelheim
Phase 3
11,800
Ahmedabad, Bengaluru, Bikaner, Kanpur, Kolkata, Maharashtra, Nagpur, Nashik
2025-07-22
Active, closed
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
NCT06981078Chronic Obstructive Pulmonary Disease
Upstream Bio Inc.
Phase 2
666
Hyderabad, Nellore, Vijayawada, Gurgaon, Rohtak, Kolhฤpur, Nagpur, New Delhi
2025-07-02
Not yet open
Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients
NCT07017036Primary Immunodeficiency Diseases (PID)
Virchow Group
Phase 3
44
Nagpur, Jaipur
2025-07-01
Recruiting
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375Heart Failure
Novo Nordisk A/S
Phase 2
200
Vadodara, Kochi, Mumbai, Nagpur, New Delhi, New Dehli, Ludhiana, Dehradun
2025-06-30
Recruiting
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362Heart Failure
Novo Nordisk A/S
Phase 2
200
Vadodara, Nagpur, New Delhi, New Dehli, Vijayawada, Chennai, Hyderabad, Dehradun
2025-06-27
Active, closed
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
NCT07030517Multiple Myeloma
Johnson & Johnson Private Limited
Phase 4
75
Bangalore, Bengaluru, Chandigarh, Jaipur, Kolkata, Mumbai, Nagpur, New Delhi
2025-05-22
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
Daiichi Sankyo
Phase 3
582
Ahmedabad, Kolkata, Mumbai, Nagpur, Nashik, Pune, Vadodara, Varanasi
2025-03-19
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
Pfizer
Phase 3
723
Guntur, Ahmedabad, Mangaluru, Mumbai, Nagpur, Nashik, Ajmer, Lucknow
2025-03-11
Recruiting
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268Sickle Cell Disease
Novo Nordisk A/S
Phase 3
510
Guwahati, Raipur, Dohad, Surat, Vadodara, Mysuru, Kozhikode, Nagpur
2025-02-17
Recruiting
Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
NCT06755450Relapsed Advanced Lymphomas
Aurigene Discovery Technologies Limited
Phase 1
40
Vadodara, Jhajjar, Bangalore, Aurangabad, Nagpur, Pune, Satara, Thane
2025-01-15
Recruiting
LIVERAGEโ„ข - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Ahemdabad, Chandigarh, Hyderabad, Afzalgunj, Jaipur, Lucknow, Nagpur, New Delhi, Rohtak
2024-11-12
Recruiting
LIVERAGEโ„ข: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Ahemdabad, Chandigarh, Hyderabad, Afzalgunj, Jaipur, Lucknow, Mohali, Nagpur, New Delhi
2024-10-14
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239Asthma
Sanofi
Phase 2
900
Calicut, Hyderabad, Kanpur, Nagpur, Pune
2024-09-30
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787Alzheimer Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Aurangabad, Nagpur, Chandigarh, Ajmer, Hyderabad, Kolkata, Varanasi
2024-09-26
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Akero Therapeutics, Inc
Phase 3
2,150
Hyderabad, Surat, Vadodara, Mysore, Thiruvananthapuram, Mumbai, Nagpur, Pune
2024-09-04
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
AstraZeneca
Phase 3
788
Delhi, Kolkata, Lucknow, Mumbai, Mysuru, Nagpur, Nashik, New Delhi
2024-08-01
By invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463Focal Epilepsy
Biohaven Therapeutics Ltd.
Phase 2
660
Hyderabad, Mangalore, Mumbai, Nagpur, New Delhi
2024-07-30
Rows per page Showing 26–50 of 124
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/nagpur

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.